ELTP (Elite Pharmaceuticals) Total Inventories : $16.24 Mil (As of Mar. 2025)

View and export this data going back to 1998. Start your Free Trial

What is Elite Pharmaceuticals Total Inventories?

Elite Pharmaceuticals's total inventories for the quarter that ended in Mar. 2025 was $16.24 Mil. Elite Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2024 to the quarter that ended in Mar. 2025 was $18.20 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Elite Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2025 was $-0.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Elite Pharmaceuticals's Days Inventory for the three months ended in Mar. 2025 was 112.96.

Inventory Turnover measures how fast the company turns over its inventory within a year. Elite Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2025 was 0.81.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Elite Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 0.57.

Elite Pharmaceuticals Total Inventories Historical Data

The historical data trend for Elite Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals Total Inventories Chart

Elite Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Total Inventories

Get a 7-Day Free Trial

5.01

6.74

9.55

12.93

16.24

Elite Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Inventories	Get a 7-Day Free Trial															12.93	13.83	14.17	20.16	16.24

Elite Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Elite Pharmaceuticals (OTCPK:ELTP) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Elite Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2025 is

	Net-Net Working Capital Per Share (Q: Mar. 2025 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(11.315	+	0.75 * 29.207	+	0.5 * 16.24	-	42.872
-	0	-	0)	/	1068.273
=	-0.00

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Elite Pharmaceuticals's Days Inventory for the three months ended in Mar. 2025 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2025 )	/	Cost of Goods Sold (Q: Mar. 2025 )	*	Days in Period
	=	18.199	/	14.701	*	365 / 4
	=	112.96

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Elite Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2025 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2025 )	/	Average Total Inventories (Q: Mar. 2025 )
	=	14.701	/	18.199
	=	0.81

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Elite Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2025 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	18.199	/	31.996
	=	0.57

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Elite Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Elite Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (OTCPK:ELTP) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

165 Ludlow Avenue, Northvale, NJ, USA, 07647

Website

https://www.elitepharma.com

Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Executives

Douglas Plassche	officer: Executive VP of Operations	165 LUDLOW AVE., NORTHVALE NJ 07647
Mark N Pellegrino	officer: CFO, Secretary, Treasurer	165 LUDLOW AVE, NORTHVALE NJ 07647
Kirko Kirkov	officer: Chief Commercial Officer	165 LUDLOW AVE, NORTHVALE NJ 07647
Chen Robert C J	officer: CFO, Secretary, Treasurer	165 LUDLOW AVENUE, NORTHVALE NJ 07647
Marc Bregman	officer: CFO, Secretary, Treasurer	C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Eugene M Pfeifer	director	C/O ELITE PHARMACEUTICALS, INC, 165, NORTHVALE NJ 07647
Davis S Caskey	director	C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVE, NORTHVALE NJ 07647
Jerry Treppel	director	93 SETON HIGHLANDS, PLYMOUTH MA 02360
Mikah Pharma, Llc	10 percent owner	165 LUDLOW AVE., NORTHVALE NJ 07647
Jeenarine Narine	director, 10 percent owner	C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Ashok G Nigalaye	director, 10 percent owner, officer: Chief Scientific Officer	C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Epic Pharma Llc	10 percent owner	227-15 NORTH CONDUIT AVE, LAURELTON NY 11413-3134
Epic Investments, Llc	10 percent owner	227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Nasrat A Hakim	director, 10 percent owner, officer: President & CEO	C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeffrey A Whitnell	director	C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVENUE, NORTHVALE NJ 07647